We are pleased to announce that Torben Jørgensen has joined ArgusEye as the new Chairman of the Board – a valuable asset to the company as we continue to innovate and expand.

With decades of experience in the biopharmaceutical and life science industry, Torben brings a rare combination of strategic insights and financial acumen. Throughout his career, he has consistently delivered transformative results – scaling organizations, driving innovation, and unlocking long-term value through focused leadership and collaboration.

A hallmark of Torben’s leadership style is his hands-on approach. He believes that being actively involved and present where day-to-day operations take place is essential to staying aligned with teams and anticipating future needs. His ability to remain grounded in the operational core while maintaining a forward-looking perspective has been central to his success.

My leadership philosophy is grounded in years of experience and shaped by my Danish roots. I prioritize transparency and open dialogue, and I like being present in the ‘engine room’. It allows me to engage with the team on a more detailed level and ensure we’re aligned and moving decisively toward our goals.

Over the course of his career, Torben has developed an ability to balance big-picture thinking with attention to operational detail. He has led organizations through significant growth, global expansion, and the development of sustainable business models. Equally important, he has developed a deep understanding of the scientific and commercial forces shaping the biopharma landscape – insights that will be invaluable as ArgusEye accelerates its own development plan.

I am drawn to companies with a strong emphasis on commercialization and internationalization, areas that have defined my career over the past 40 years. Being part of a scale-up again is energizing. With my experience, I believe I can add value across multiple dimensions. At this stage of growth that ArgusEye is in, there are numerous challenges to navigate, and I’m confident in my ability to help the team stay focused, prioritize effectively, and make the most of available resources.

Torben also brings a broad and current perspective on the evolving biopharma and life science landscape, including emerging trends and challenges. His industry expertise will support ArgusEye’s ambition to become a global leader in enabling technologies for bioprocessing.

I see significant potential for ArgusEye’s to establish a strong foothold in supporting the biopharmaceutical industry, particularly by helping big pharma companies, CDMOs, CROs and CMOs streamline their workflows. Enabling these organizations to operate more efficiently and deliver results faster is critical to accelerating drug development, and that’s exactly where ArgusEye can make a meaningful impact.

We are thrilled to welcome Torben to our board. His guidance will be invaluable in helping us strengthen our position in the biopharmaceutical space, where our vision is to transform the development and production of biopharmaceuticals.

As we conclude the first month of 2025, it is a great time to reflect on the transformative journey of 2024 and set our sights for the year ahead. The past year was marked by significant achievements in innovation, collaboration, and growth—each bringing us closer to our goal of fundamentally reshaping the pharmaceutical industry. Looking further into 2025, we are excited about the opportunities that await us and remain committed to driving groundbreaking innovation and delivering impactful solutions for the industry.

2024 brought significant advancements in both business and technology for ArgusEye. It was the year we successfully doubled our team, relocated to new facilities, and had our first product launch—a productive year to say the least!

Here is a closer look at some of the milestones that defined 2024:

At the start of the year, we took a monumental step forward by relocating from a shared laboratory at Linköping university to our own 750m² facility, housing laboratories, production facilities, and several office spaces. This move was more than just a change of address, it is a testament to the tangible growth and expansion the company is experiencing. Our new premises provide plenty of office and laboratory space for continued innovation and growth in the coming years.

In May, we closed an oversubscribed funding round of €2.8 million. The round was led by Voima Ventures, a Nordic early-stage investor specializing in science-driven innovation, and co-lead with Eir Ventures, a leading Scandinavian life science venture capital fund. This investment is crucial for scaling our operations and further developing the Auga™ platform, as we strive to deliver a comprehensive solution for the entire pharmaceutical process chain.

To meet the increasing demand for our solutions, we achieved significant growth in our workforce, more than doubling the size of our team in just one year. This expansion has brought a wealth of diverse talent and expertise into ArgusEye, further strengthening our ability to innovate, execute, and deliver exceptional results.

One of the year’s standout moments was the launch of the Auga™ platform and AugaOne™. Auga™ is a versatile sensor platform designed for real-time bioprocess monitoring, while AugaOne™ is the first product in the lineup—a standalone sensor system that seamlessly integrates with chromatography equipment, providing valuable in-line data in real-time during product purification. This launch represents a significant milestone in our objective to develop a versatile technology that can be seamlessly integrated throughout the bioprocess.

Explore the Auga™ platform
Explore AugaOne™

Throughout the year, we conducted several successful demonstrations for some of the world’s leading pharmaceutical companies. While we have continued our demonstrations in Europe, we also held our first demonstrations in the U.S., spanning from the East Coast to the West Coast. These demonstrations have further validated the potential of our technology and opened new opportunities for collaboration within the U.S. market.

For the third consecutive year ArgusEye secured a spot on Ny Teknik’s prestigious ‘33-Listan’ and by that earned the elusive status of a ‘gold company’. The list showcases Sweden’s most promising young tech companies, each eligible for up to three appearances, with progressively stricter criteria applied each time. Being recognized on the list for three consecutive years highlights the significant progress we have made and emphasizes the rapid pace at which we achieved this growth.

With a year of impressive achievements behind us, we are more inspired than ever to push boundaries in 2025. Our focus will remain on advancing our technologies, expanding our reach, and delivering solutions that empower the pharmaceutical industry to thrive. We are dedicated to continue this journey of innovation and collaboration, fueled by the belief that the best is yet to come.

While we can’t predict the future, we are committed to several key goals this year. One major focus is expanding our team and expertise to accelerate our progress even further and we plan to grow our sensor lineup. Additionally, an exciting milestone awaits—a highly anticipated product launch, marking the release of our second portfolio product.

At ArgusEye, our patented technology leverages nanoplasmonic sensing and fiber optics to create Localized Surface Plasmon Resonance (LSPR) – a powerful phenomenon with transformative potential in biosensing.

Localized Surface Plasmon Resonance (LSPR) occurs when light interacts with the surface of metal nanoparticles, causing the free electrons to oscillate collectively. These oscillations, called plasmon, remain confined to the nanoparticle’s surface rather than propagating through the material. LSPR is extremely sensitive to variations in the nanoparticle’s local environment, including changes in refractive index, particle size and shape, or the presence of molecules on its surface.

By attaching ligands, specific capturing molecules, the technology can be applied for biosensing. When target molecules – such as proteins, viruses, or other biomolecules – bind to these ligands, the interaction causes a measurable shift in the LSPR signal. This measurable shift allows for the detection and quantification of the target molecules. Due to its high sensitivity, LSPR is well suited for various applications, including detecting biomolecules, monitoring biological interactions in real time, and screening drugs – making it a powerful technique for biosensing.

LSPR offers several key benefits for the biopharmaceutical industry, such as specific detection, the ability to handle complex environments, insensitivity to changes in the process, and the ability to provide immediate response. Therefore, it enables real-time monitoring of critical quality attributes, either in- or on-line, which helps optimize process development, enhance production efficiency, and accelerate the development of new biological drugs. In the future, advantages like this will make LSPR an invaluable tool for diagnostics, molecular analysis, and the optimization of biopharmaceutical processing.

At ArgusEye, we are utilizing the LSPR technology to realize our vision: reshaping the development and production of biologics. We aim to optimize product development by leveraging real-time, in-line data. In the short term, this will significantly reduce lead times, while in the long term, enabling continuous and automated production. Our ultimate goal is to help life-saving treatments reach the market faster and become accessible to a substantially larger population.

Earlier this year, we introduced the Auga™ platform alongside our flagship product, AugaOne™. Today, the platform provides real-time information that can enable the quantification of monoclonal antibodies (mAbs). In the future, the platform will be developed to realize our vision. To do so, our R&D team is currently focusing on not only the development of new sensors but also on creating hardware that provides both in-line and on-line data. Our goal is to advance ArgusEye’s LSPR technology to the point where it can be integrated throughout the bioprocess of some of our most critical medicines, such as mAbs, cell and gene therapy, and much more. This integration will then span from early upstream processes to late-stage formulation, allowing us to measure both the product and other critical quality attributes during process development and production.

If you are interested in further exploring how our sensors can enhance your bioprocesses and drive efficiency in your operations, we invite you to reach out to our COO, Nathalie Elsässer, at nathalie.elsasser@arguseye.se.